Acea Biotech, Inc.
San Francisco, CA 94111, US
Corifungin, a small molecule discovered by Dr. Josefino Tunac, is a broad-spectrum, water soluble, anti-fungal and anti-amebic drug belonging to the polyene macrolide class of antibiotics.
Corifungin can be developed to satisfy the medical needs of a broad range of indications ranging from systemic internal fungal infections of immunocompromised patients to vulvovaginal candidiasis (yeast infections) and onychomycosis (toe fungus). Corifungin can be administered intravenously, orally, via a spray, and topically. Acea has completed a number of preclinical models establishing the safety and efficacy of Corifungin in the treatment of a wide variety of mycotic and parasitic infections in accepted animal models. In fact, Corifungin’s remarkable efficacy in the treatment of difficult- or impossible-to-treat parasitic infections resulted in the FDA issuing Orphan Drug Designations for two indications: (1) visceral leishmaniasis and (2) primary amoebic meningoencephalitis (PAM).
Corifungin is a broad spectrum antifungal that will compete effectively against existing, more toxic alternatives. It has the advantage of being able to be used as a “step down” therapy i.e. given in the hospital and then later given as a pill for follow up treatment.
Product is protected under US Patent No. 9,212,201 B2 with the EU patent pending.
Upon completion of clinical trial, efforts will be made to license the drug to the appropriate pharmaceutical company(ies) for further development.
Products / Services
Corifungin is a small molecule, antifungal drug. We are developing the drug to be used in all forms of administration including, intravenously, as a pill, as a spray, and as a topical.
The drug has undergone extensive pre-clinical animal testing and is now ready for Phase I human trials.
Chief Executive Officer
Milton K Reeder
Mr. Reeder is Chief Executive Officer and co-founder of Acea Biotech, Inc. Mr. Reeder and Dr. Tunac have teamed up to bring Acea Biotech into the forefront of antimicrobial drug innovation. Mr. Reeder is a seasoned investor and business executive. He has been CEO of several private and public companies and managed those entities through growth and contraction cycles. His last public company was merged into ProLogis (NYSE:PLD) for $1.2 billion. Mr. Reeder is also CEO of Accent Capital Partners, LLC, a San Francisco-based investment-banking firm that he founded as well as CEO of Accent Capital Advisors, an NASD broker/dealer. Accent specializes in assisting young companies in a variety of industries. Mr. Reeder has been active in the financial community for over twenty-eight years. He has successfully completed over $3.0 billion in financial transactions including the public offering of common shares, preferred shares, investment grade rated debt as well as private offerings of equity se
Josefino Tunac, Ph.D.
Dr. Tunac is Chief Scientific Officer, co-founder of Acea Biotech, Inc. and discoverer of Corifungin. Besides Acea, Dr. Tunac also continues his research activities at other pharmaceutical ventures. In 1987, Dr. Tunac founded a privately held pharmaceutical company, Fermical, Inc. Dr. Tunac discovered and developed a number of biotech-based drugs including infectious and chronic diseases. These drugs were used to start biotech companies including: Supergen, Inc. [NASDAQ:SUPG], Dublin, CA (anticancer drugs mitomycin C, pentostatin); Altaria Pharmaceuticals (Formerly JJ Pharma), Scottsdale, AZ (JJP-10/11 lipid modulator drugs and JJP-12 antiarthritic); Adevida Biotica, Corp., Oxford, MI (Adenzym™ to treat cellular ‘corrosion” Vintarex treatment for metabolic acidosis), Farmaceutix, LLC, Ferndale MI (diagnostics and therapies for vascular diseases). Dr. Tunac invented and marketed the Tunair™ flask system (a laboratory culture flask now used worldwide) and the Airmentor™ (a novel bioreac